PART I The following description of our business contains forward-looking statements relating to future events or our future financial or operating performance that involve risks and uncertainties, as set forth above under Special Note Regarding Forward-Looking Statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors described in the Annual Report, including those set forth above in the Special Cautionary Not...
Q2 FY2026 — expected 2026-08-20
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | AIBT | discussed_in_filing Artificial Intelligence | |
| topic_mention | AIBT | discussed_in_filing Cybersecurity | |
| topic_mention | AIBT | discussed_in_filing Trusted Computing | |
| topic_mention | AIBT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | AIBT | discussed_in_filing Robotics | |
| topic_mention | AIBT | discussed_in_filing Capital Expenditure | |
| topic_mention | AIBT | discussed_in_filing Supply Chain | |
| topic_mention | AIBT | discussed_in_filing Regulation | |
| topic_mention | AIBT | discussed_in_filing Enterprise | |
| topic_mention | AIBT | discussed_in_filing Healthcare & Bio | |
| topic_mention | AIBT | discussed_in_filing AI Compute | |
| topic_mention | AIBT | discussed_in_filing Platform & Ecosystem | |
| topic_mention | AIBT | discussed_in_filing Sovereign & Government | |
| topic_mention | AIBT | discussed_in_filing Artificial Intelligence | |
| topic_mention | AIBT | discussed_in_filing Cybersecurity | |
| topic_mention | AIBT | discussed_in_filing Trusted Computing | |
| topic_mention | AIBT | discussed_in_filing Blockchain & Crypto | |
| topic_mention | AIBT | discussed_in_filing Robotics | |
| topic_mention | AIBT | discussed_in_filing Capital Expenditure | |
| topic_mention | AIBT | discussed_in_filing Supply Chain |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-11 | 2024-12-31 | 0001096906-25-000487 | EDGAR | 22K words |
| 2024-04-23 | 2023-12-31 | 0001096906-24-000907 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001096906-23-000683 | EDGAR | — |
| 2022-04-14 | 2021-12-31 | 0001096906-22-000867 | EDGAR | — |
| 2021-04-15 | 2020-12-31 | 0001096906-21-000766 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001445866-20-000291 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-19 | 2025-09-30 | 0001096906-25-001895 | EDGAR | 13K words |
| 2025-08-19 | 2025-06-30 | 0001096906-25-001375 | EDGAR | — |
| 2025-05-20 | 2025-03-31 | 0001096906-25-000861 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001096906-24-002137 | EDGAR | — |
| 2024-08-19 | 2024-06-30 | 0001096906-24-001763 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001096906-24-001146 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001096906-23-002130 | EDGAR | — |
| 2023-08-17 | 2023-06-30 | 0001096906-23-001623 | EDGAR | — |
| 2023-07-14 | 2023-03-31 | 0001096906-23-001409 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001096906-22-002761 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001096906-22-001838 | EDGAR | — |
| 2022-05-23 | 2022-03-31 | 0001096906-22-001262 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-03-24 | 0001096906-25-000287 | EDGAR | 3K words |
| 2024-08-21 | 0001096906-24-001786 | EDGAR | — |
| 2024-03-28 | 0001096906-24-000650 | EDGAR | — |
| 2023-12-05 | 0001096906-23-002316 | EDGAR | — |
| 2023-05-03 | 0001096906-23-000961 | EDGAR | — |
| 2023-02-22 | 0001096906-23-000428 | EDGAR | — |
| 2022-05-19 | 0001096906-22-001188 | EDGAR | — |
| 2022-01-14 | 0001096906-22-000130 | EDGAR | — |
| 2021-01-21 | 0001096906-21-000120 | EDGAR | — |
| 2021-01-20 | 0001096906-21-000115 | EDGAR | — |
46 total filings indexed. 18 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001763329 |
| Ticker | AIBT |
| Exchange | OTC |
| SIC | 2833: Medicinal Chemicals & Botanical Products |
| Incorporated | NV |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report